<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="es"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Enferm Infecc Microbiol Clin</journal-id><journal-id journal-id-type="iso-abbrev">Enferm. Infecc. Microbiol. Clin</journal-id><journal-title-group><journal-title>Enfermedades Infecciosas Y Microbiologia Clinica</journal-title></journal-title-group><issn pub-type="ppub">0213-005X</issn><issn pub-type="epub">1578-1852</issn><publisher><publisher-name>Elsevier Espa&#x000f1;a S.L.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">S0213-005X(05)75156-9</article-id><article-id pub-id-type="doi">10.1016/S0213-005X(05)75156-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Situaci&#x000f3;n actual en el desarrollo de una vacuna preventiva frente al VIH</article-title><trans-title-group xml:lang="en"><trans-title>Present situation in the development of a preventive HIV vaccine</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Alcam&#x000ed;</surname><given-names>Jos&#x000e9;</given-names></name><email>ppalcami@isciii.es</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author"><name><surname>Joseph Munn&#x000e9;</surname><given-names>Joan</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>&#x000c1;ngeles Mu&#x000f1;oz-Fern&#x000e1;ndez</surname><given-names>Mar&#x000ed;a</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Esteban</surname><given-names>Mariano</given-names></name><xref rid="aff4" ref-type="aff">d</xref></contrib><aff id="aff1"><label>a</label>Unidad de Inmunopatolog&#x000ed;a del Sida. Centro Nacional de Microbiolog&#x000ed;a. Instituto de Salud Carlos III. Majadahonda. Espa&#x000f1;a</aff><aff id="aff2"><label>b</label>Estudio y Desarrollo de Vacunas frente al VIH. Unidad Estudio del Sida. Hospital Cl&#x000ed;nic. Institut d&#x02019;Investigacions Biomediques August Pi i Sunyer (IDIBAPS). Facultad de Medicina. Universidad de Barcelona. Hospital Cl&#x000ed;nic. Barcelona. Espa&#x000f1;a</aff><aff id="aff3"><label>c</label>Laboratorio de Inmunobiolog&#x000ed;a Molecular. Hospital General Universitario Gregorio Mara&#x000f1;&#x000f3;n. Madrid. Espa&#x000f1;a</aff><aff id="aff4"><label>d</label>Centro Nacional de Biotecnolog&#x000ed;a. Consejo Superior de Investigaciones Cient&#x000ed;ficas (CSIC). Campus Universidad Aut&#x000f3;noma. Madrid. Espa&#x000f1;a</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x0204e;</label>Correspondencia: Dr. J. Alcam&#x000ed;. Unidad de Inmunopatolog&#x000ed;a del Sida. Centro Nacional de Microbiolog&#x000ed;a. Instituto de Salud Carlos III. Ctra. Pozuelo, 2. 28220 Majadahonda. Madrid. Espa&#x000f1;a. <email>ppalcami@isciii.es</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>6</day><month>1</month><year>2009</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>7</month><year>2005</year></pub-date><pub-date pub-type="epub"><day>6</day><month>1</month><year>2009</year></pub-date><volume>23</volume><fpage>5</fpage><lpage>14</lpage><permissions><copyright-statement>Copyright &#x000a9; 2005 Elsevier Espa&#x000f1;a S.L. All rights reserved.</copyright-statement><copyright-year>2005</copyright-year><copyright-holder>Elsevier Espa&#x000f1;a S.L.</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract><p>El avance de la epidemia de sida ha convertido la obtenci&#x000f3;n de una vacuna eficaz frente al virus de la inmunodeficiencia humana (VIH) como un objetivo cient&#x000ed;fico prioritario. En el momento actual no disponemos de una vacuna preventiva frente a la infecci&#x000f3;n por el VIH y en ning&#x000fa;n modelo animal se ha conseguido la protecci&#x000f3;n frente a la infecci&#x000f3;n. En esta revisi&#x000f3;n se analizan las dificultades existentes en el desarrollo de una vacuna contra el sida, en especial los mecanismos de escape viral a la respuesta inmunitaria y se describen los prototipos de vacunas preventivas y terap&#x000e9;uticas en desarrollo y los resultados obtenidos. Por otra parte se sit&#x000fa;a esta investigaci&#x000f3;n en el contexto sanitario, econ&#x000f3;mico y social de la pandemia de sida y se analizan las pol&#x000e9;micas actualmente planteadas en el desarrollo de ensayos cl&#x000ed;nicos con los diferentes tipos de vacunas.</p></abstract><trans-abstract xml:lang="en"><p>Due to the uncontrolled progression of the aids epidemic the development of an HIV vaccine has become a major objective of scientific research. An effective preventive vaccine against human immunodeficiency virus (HIV) is not available and sterilising immunity has not yet been achieved in animal models. In this review major challenges in developing an aids vaccine, in particular the mechanisms involved in viral escape to the immune response are analysed, and results obtained with the different prototypes of therapeutic and preventive vaccines summarized. Finally, social, economic and health aspects related to research on HIV vaccines and present controversies regarding the development of clinical trials are discussed.</p></trans-abstract><kwd-group><title>Palabras clave</title><kwd>VIH</kwd><kwd>Sida</kwd><kwd>Vacuna</kwd><kwd>Mecanismos de escape viral</kwd><kwd>Inmunidad antiviral</kwd></kwd-group><kwd-group xml:lang="en"><title>Key words</title><kwd>HIV</kwd><kwd>Aids</kwd><kwd>Vaccine</kwd><kwd>Viral scape mechanisms</kwd><kwd>Antiviral immunity</kwd></kwd-group></article-meta></front><back><ref-list><title>Bibliograf&#x000ed;a</title><ref id="bib1"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>WHO</collab></person-group><chapter-title>UNAIDS report on the global HIV/AIDS epidemic</chapter-title><year>2003</year><publisher-name>WHO</publisher-name><publisher-loc>Gen&#x000e8;ve</publisher-loc></element-citation></ref><ref id="bib2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nossal</surname><given-names>G.J.V.</given-names></name></person-group><article-title>The global alliance for vaccines and immunization: a millennial challenge</article-title><source>Nature Immunol</source><volume>1</volume><year>2000</year><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10881161</pub-id></element-citation></ref><ref id="bib3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esparza</surname><given-names>J.</given-names></name><name><surname>Bhamarapravati</surname><given-names>N.</given-names></name></person-group><article-title>Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how?</article-title><source>Lancet</source><volume>355</volume><year>2000</year><fpage>2061</fpage><lpage>2066</lpage><pub-id pub-id-type="pmid">10885368</pub-id></element-citation></ref><ref id="bib4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nabel</surname><given-names>G.J.</given-names></name></person-group><article-title>Challenges and opportunities for development of an AIDS vaccines</article-title><source>Nature</source><volume>410</volume><year>2001</year><fpage>1002</fpage><lpage>1006</lpage><pub-id pub-id-type="pmid">11309631</pub-id></element-citation></ref><ref id="bib5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMichael</surname><given-names>A.</given-names></name><name><surname>Hanke</surname><given-names>T.</given-names></name></person-group><article-title>HIV vaccines 1983-2003</article-title><source>Nat Med</source><volume>9</volume><year>2003</year><fpage>874</fpage><lpage>880</lpage><pub-id pub-id-type="pmid">12835708</pub-id></element-citation></ref><ref id="bib6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zinkernagel</surname><given-names>R.</given-names></name><name><surname>Doherty</surname><given-names>P.</given-names></name></person-group><article-title>MHC-restricted cytotoxic T-cells: studies on the biological role of major transplantation antigens determining T-cell restriction-specificity, function and responsiveness</article-title><source>Adv Immunol</source><volume>27</volume><year>1979</year><fpage>51</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">92183</pub-id></element-citation></ref><ref id="bib7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>M.H.</given-names></name><name><surname>Simon</surname><given-names>R.</given-names></name></person-group><article-title>Genomewide conserved epitope profiles of HIV-1 predicted by biophysical properties of MHC binding peptides</article-title><source>J Comput Biol</source><volume>11</volume><year>2004</year><fpage>125</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">15072692</pub-id></element-citation></ref><ref id="bib8"><label>8.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bandr&#x000e9;s</surname><given-names>J.A.</given-names></name><name><surname>Zolla-Pazner</surname><given-names>S.</given-names></name></person-group><chapter-title>Inmunidad humoral en la infecci&#x000f3;n por el VIH</chapter-title><person-group person-group-type="editor"><name><surname>Gonz&#x000e1;lez</surname><given-names>J.</given-names></name><name><surname>Moreno</surname><given-names>S.</given-names></name><name><surname>Rubio</surname><given-names>R.</given-names></name></person-group><source>Infecci&#x000f3;n por el VIH 1999</source><year>1999</year><publisher-name>Doyma</publisher-name><publisher-loc>Madrid</publisher-loc></element-citation></ref><ref id="bib9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nabel</surname><given-names>G.J.</given-names></name><name><surname>Sullivan</surname><given-names>N.J.</given-names></name></person-group><article-title>antibodies and resistance to natural HIV infection</article-title><source>N Engl J Med</source><volume>343</volume><year>2000</year><fpage>17</fpage><lpage>19</lpage></element-citation></ref><ref id="bib10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mascola</surname><given-names>J.R.</given-names></name><name><surname>Stiegler</surname><given-names>G.</given-names></name><name><surname>VanCott</surname><given-names>T.C.</given-names></name><name><surname>Katinger</surname><given-names>H.</given-names></name><name><surname>Carpenter</surname><given-names>C.B.</given-names></name><name><surname>Hanson</surname><given-names>C.E.</given-names></name></person-group><article-title>Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies</article-title><source>Nat Med</source><volume>6</volume><year>2000</year><fpage>207</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">10655111</pub-id></element-citation></ref><ref id="bib11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richman</surname><given-names>D.D.</given-names></name><name><surname>Wrin</surname><given-names>T.</given-names></name><name><surname>Little</surname><given-names>S.J.</given-names></name><name><surname>Petropoulos</surname><given-names>C.J.</given-names></name></person-group><article-title>Rapid evolution of the neutralizing antibody response to HIV type 1 infection</article-title><source>Proc Natl Acad Sci U S A</source><volume>100</volume><year>2003</year><fpage>4144</fpage><lpage>4149</lpage><pub-id pub-id-type="pmid">12644702</pub-id></element-citation></ref><ref id="bib12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>H.L.</given-names></name><name><surname>Montefiori</surname><given-names>D.C.</given-names></name><name><surname>Johnson</surname><given-names>R.P.</given-names></name><name><surname>Manson</surname><given-names>K.H.</given-names></name><name><surname>Kalish</surname><given-names>M.L.</given-names></name><name><surname>Lifson</surname><given-names>J.D.</given-names></name></person-group><article-title>Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations</article-title><source>Nat Med</source><volume>5</volume><year>1999</year><fpage>526</fpage><lpage>534</lpage><pub-id pub-id-type="pmid">10229229</pub-id></element-citation></ref><ref id="bib13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>J.P.</given-names></name><name><surname>Burton</surname><given-names>D.R.</given-names></name></person-group><article-title>HIV-1 neutralizing antibodies: how full is the bottle?</article-title><source>Nat Med</source><volume>5</volume><year>1999</year><fpage>142</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">9930854</pub-id></element-citation></ref><ref id="bib14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burton</surname><given-names>D.R.</given-names></name></person-group><article-title>Antibodies, viruses and vaccines</article-title><source>Nat Rev Immunol</source><volume>2</volume><year>2002</year><fpage>706</fpage><lpage>713</lpage><pub-id pub-id-type="pmid">12209139</pub-id></element-citation></ref><ref id="bib15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burton</surname><given-names>D.R.</given-names></name><name><surname>Desrosiers</surname><given-names>R.C.</given-names></name><name><surname>Doms</surname><given-names>R.W.</given-names></name><name><surname>Koff</surname><given-names>W.C.</given-names></name><name><surname>Kwong</surname><given-names>P.D.</given-names></name><name><surname>Moore</surname><given-names>J.P.</given-names></name></person-group><article-title>HIV vaccine design and the neutralizing antibody problem</article-title><source>Nat Immunol</source><volume>5</volume><year>2004</year><fpage>233</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">14985706</pub-id></element-citation></ref><ref id="bib16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMichael</surname><given-names>A.J.</given-names></name><name><surname>Rowland-Jones</surname><given-names>S.L.</given-names></name></person-group><article-title>Cellular immune responses to HIV</article-title><source>Nature</source><volume>410</volume><year>2001</year><fpage>980</fpage><lpage>987</lpage><pub-id pub-id-type="pmid">11309628</pub-id></element-citation></ref><ref id="bib17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>E.S.</given-names></name><name><surname>Billingsley</surname><given-names>J.M.</given-names></name><name><surname>Caliendo</surname><given-names>A.M.</given-names></name><name><surname>Boswell</surname><given-names>S.L.</given-names></name><name><surname>Sax</surname><given-names>P.E.</given-names></name><name><surname>Kalams</surname><given-names>S.A.</given-names></name></person-group><article-title>Vigorous HIV-1-specific CD4+T cell responses associated with control of viremia</article-title><source>Science</source><volume>278</volume><year>1997</year><fpage>1447</fpage><lpage>1450</lpage><pub-id pub-id-type="pmid">9367954</pub-id></element-citation></ref><ref id="bib18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogg</surname><given-names>G.S.</given-names></name><name><surname>Jin</surname><given-names>X.</given-names></name><name><surname>Bonhoeffe</surname><given-names>S.</given-names></name><name><surname>Dunbar</surname><given-names>R.P.</given-names></name><name><surname>Nowak</surname><given-names>M.A.</given-names></name><name><surname>Monard</surname><given-names>S.</given-names></name></person-group><article-title>Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA</article-title><source>Science</source><volume>279</volume><year>1998</year><fpage>2103</fpage><lpage>2106</lpage><pub-id pub-id-type="pmid">9516110</pub-id></element-citation></ref><ref id="bib19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>E.S.</given-names></name><name><surname>Altfeld</surname><given-names>M.</given-names></name><name><surname>Poon</surname><given-names>S.H.</given-names></name><name><surname>Phillips</surname><given-names>M.N.</given-names></name><name><surname>Wilkes</surname><given-names>B.M.</given-names></name><name><surname>Eldridge</surname><given-names>R.L.</given-names></name></person-group><article-title>Immune control of HIV-1 after early treatment of acute infection</article-title><source>Nature</source><volume>407</volume><year>2000</year><fpage>523</fpage><lpage>526</lpage><pub-id pub-id-type="pmid">11029005</pub-id></element-citation></ref><ref id="bib20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitcher</surname><given-names>C.J.</given-names></name><name><surname>Quittner</surname><given-names>C.</given-names></name><name><surname>Paterson</surname><given-names>D.M.</given-names></name><name><surname>Connors</surname><given-names>M.</given-names></name><name><surname>Koup</surname><given-names>R.A.</given-names></name><name><surname>Maino</surname><given-names>V.C.</given-names></name></person-group><article-title>HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression</article-title><source>Nature Med</source><volume>5</volume><year>1999</year><fpage>518</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">10229228</pub-id></element-citation></ref><ref id="bib21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richman</surname><given-names>D.</given-names></name></person-group><article-title>The challenge of immune control of immunodeficiency virus</article-title><source>J Clin Invest</source><volume>104</volume><year>1999</year><fpage>677</fpage><lpage>678</lpage><pub-id pub-id-type="pmid">10491402</pub-id></element-citation></ref><ref id="bib22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metzner</surname><given-names>K.J.</given-names></name><name><surname>Jin</surname><given-names>X.</given-names></name><name><surname>Lee</surname><given-names>F.V.</given-names></name><name><surname>Gettie</surname><given-names>A.</given-names></name><name><surname>Bauer</surname><given-names>D.E.</given-names></name><name><surname>Di Mascio</surname><given-names>M.</given-names></name></person-group><article-title>Effects of in vivo CD8+T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine</article-title><source>J Exp Med</source><volume>191</volume><year>2000</year><fpage>1921</fpage><lpage>1931</lpage><pub-id pub-id-type="pmid">10839807</pub-id></element-citation></ref><ref id="bib23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomson</surname><given-names>M.M.</given-names></name><name><surname>P&#x000e9;rez-&#x000c1;lvarez</surname><given-names>L.</given-names></name><name><surname>N&#x000e1;jera</surname><given-names>R.</given-names></name></person-group><article-title>Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy</article-title><source>Lancet Infect Dis</source><volume>2</volume><year>2002</year><fpage>461</fpage><lpage>471</lpage><pub-id pub-id-type="pmid">12150845</pub-id></element-citation></ref><ref id="bib24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Letvin</surname><given-names>N.L.</given-names></name><name><surname>Walker</surname><given-names>B.D.</given-names></name></person-group><article-title>Immunopathogenesis and immunotherapy in AIDS virus infections</article-title><source>Nat Med</source><volume>9</volume><year>2003</year><fpage>861</fpage><lpage>866</lpage><pub-id pub-id-type="pmid">12835706</pub-id></element-citation></ref><ref id="bib25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borrow</surname><given-names>P.</given-names></name><name><surname>Lewicki</surname><given-names>H.</given-names></name><name><surname>Wei</surname><given-names>X.</given-names></name><name><surname>Horwitz</surname><given-names>M.S.</given-names></name><name><surname>Peffer</surname><given-names>N.</given-names></name><name><surname>Meyers</surname><given-names>H.</given-names></name></person-group><article-title>Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus</article-title><source>Nat Med</source><volume>3</volume><year>1997</year><fpage>205</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">9018240</pub-id></element-citation></ref><ref id="bib26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Connor</surname><given-names>D.</given-names></name><name><surname>Hallen</surname><given-names>T.M.</given-names></name><name><surname>Vogel</surname><given-names>T.U.</given-names></name><name><surname>Jing</surname><given-names>P.</given-names></name><name><surname>DeSouza</surname><given-names>I.P.</given-names></name><name><surname>Dodds</surname><given-names>E.</given-names></name></person-group><article-title>Acute phase citotoxic T lymphocyte escape is a hallmarg of simian immunodeficiency virus infection</article-title><source>Nature Med</source><volume>8</volume><year>2002</year><fpage>493</fpage><lpage>499</lpage><pub-id pub-id-type="pmid">11984594</pub-id></element-citation></ref><ref id="bib27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brander</surname><given-names>C.</given-names></name><name><surname>Hartman</surname><given-names>K.E.</given-names></name><name><surname>Trocha</surname><given-names>A.K.</given-names></name><name><surname>Jones</surname><given-names>N.G.</given-names></name><name><surname>Johnson</surname><given-names>R.P.</given-names></name><name><surname>Korber</surname><given-names>B.</given-names></name></person-group><article-title>Lack of strong immune selection pressure by the immunodominant, HLA-A*0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection</article-title><source>J Clin Invest</source><volume>101</volume><year>1998</year><fpage>2559</fpage><lpage>2566</lpage><pub-id pub-id-type="pmid">9616227</pub-id></element-citation></ref><ref id="bib28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Migueles</surname><given-names>S.A.</given-names></name><name><surname>Laborico</surname><given-names>A.C.</given-names></name><name><surname>Shupert</surname><given-names>W.L.</given-names></name><name><surname>Sabbaghian</surname><given-names>M.S.</given-names></name><name><surname>Rabin</surname><given-names>R.</given-names></name><name><surname>Hallahan</surname><given-names>C.W.</given-names></name></person-group><article-title>HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors</article-title><source>Nat Immunol</source><volume>3</volume><year>2002</year><fpage>1061</fpage><lpage>1068</lpage><pub-id pub-id-type="pmid">12368910</pub-id></element-citation></ref><ref id="bib29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>O.O.</given-names></name></person-group><article-title>CTL ontogeny and viral escape: implications for HIV-1 vaccine design</article-title><source>Trends Immunol</source><volume>25</volume><year>2004</year><fpage>138</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">15036041</pub-id></element-citation></ref><ref id="bib30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dell</surname><given-names>H.</given-names></name></person-group><article-title>HIV-tailored to fit</article-title><source>Drug Discov Today</source><volume>9</volume><year>2004</year><fpage>101</fpage><pub-id pub-id-type="pmid">14968761</pub-id></element-citation></ref><ref id="bib31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwong</surname><given-names>P.D.</given-names></name><name><surname>Doyle</surname><given-names>M.L.</given-names></name><name><surname>Casper</surname><given-names>D.J.</given-names></name><name><surname>Cicala</surname><given-names>C.</given-names></name><name><surname>Leavitt</surname><given-names>S.A.</given-names></name><name><surname>Majeed</surname><given-names>S.</given-names></name></person-group><article-title>HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites</article-title><source>Nature</source><volume>420</volume><year>2002</year><fpage>678</fpage><lpage>682</lpage><pub-id pub-id-type="pmid">12478295</pub-id></element-citation></ref><ref id="bib32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>X.</given-names></name><name><surname>Decker</surname><given-names>J.M.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Hui</surname><given-names>H.</given-names></name><name><surname>Kappes</surname><given-names>J.C.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name></person-group><article-title>Antibody neutralization and escape by HIV-1</article-title><source>Nature</source><volume>422</volume><year>2003</year><fpage>307</fpage><lpage>312</lpage><pub-id pub-id-type="pmid">12646921</pub-id></element-citation></ref><ref id="bib33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stahl-Hennig</surname><given-names>C.</given-names></name><name><surname>Steinman</surname><given-names>R.M.</given-names></name><name><surname>Tenner-Racz</surname><given-names>K.</given-names></name><name><surname>Pope</surname><given-names>M.</given-names></name><name><surname>Stolte</surname><given-names>N.</given-names></name><name><surname>M&#x000e4;tz-Rensing</surname><given-names>K.</given-names></name></person-group><article-title>Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus</article-title><source>Science</source><volume>285</volume><year>1999</year><fpage>1261</fpage><lpage>1265</lpage><pub-id pub-id-type="pmid">10455052</pub-id></element-citation></ref><ref id="bib34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haase</surname><given-names>A.T.</given-names></name></person-group><article-title>Population biology of HIV-1 infection: viral and CD4+T cell demographics and dynamics in lymphatic tissues</article-title><source>Annu Rev Immunol</source><volume>17</volume><year>1999</year><fpage>625</fpage><lpage>656</lpage><pub-id pub-id-type="pmid">10358770</pub-id></element-citation></ref><ref id="bib35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blankson</surname><given-names>J.N.</given-names></name><name><surname>Persaud</surname><given-names>D.</given-names></name><name><surname>Siliciano</surname><given-names>R.F.</given-names></name></person-group><article-title>The challenge of viral reservoirs in HIV-1 infection</article-title><source>Annu Rev Med</source><volume>53</volume><year>2002</year><fpage>557</fpage><lpage>593</lpage><pub-id pub-id-type="pmid">11818490</pub-id></element-citation></ref><ref id="bib36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geijtenbeek</surname><given-names>T.B.</given-names></name><name><surname>Kwon</surname><given-names>D.S.</given-names></name><name><surname>Torensma</surname><given-names>R.</given-names></name><name><surname>Van Vliet</surname><given-names>S.J.</given-names></name><name><surname>Van Duijnhoven</surname><given-names>G.C.</given-names></name><name><surname>Middel</surname><given-names>J.</given-names></name></person-group><article-title>DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells</article-title><source>Cell</source><volume>100</volume><year>2000</year><fpage>587</fpage><lpage>597</lpage><pub-id pub-id-type="pmid">10721995</pub-id></element-citation></ref><ref id="bib37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douek</surname><given-names>D.C.</given-names></name><name><surname>Brenchley</surname><given-names>J.M.</given-names></name><name><surname>Betts</surname><given-names>M.R.</given-names></name><name><surname>Ambrozak</surname><given-names>D.R.</given-names></name><name><surname>Hill</surname><given-names>B.J.</given-names></name><name><surname>Okamoto</surname><given-names>Y.</given-names></name></person-group><article-title>HIV preferentially infects HIV-specific CD4+ T cells</article-title><source>Nature</source><volume>417</volume><year>2002</year><fpage>95</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">11986671</pub-id></element-citation></ref><ref id="bib38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daniel</surname><given-names>M.D.</given-names></name><name><surname>Kirchhoff</surname><given-names>F.</given-names></name><name><surname>Czajak</surname><given-names>S.C.</given-names></name><name><surname>Sehgal</surname><given-names>P.K.</given-names></name><name><surname>Desrosiers</surname><given-names>R.C.</given-names></name></person-group><article-title>Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene</article-title><source>Science</source><volume>258</volume><year>1992</year><fpage>1938</fpage><lpage>1941</lpage><pub-id pub-id-type="pmid">1470917</pub-id></element-citation></ref><ref id="bib39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deacon</surname><given-names>N.J.</given-names></name><name><surname>Tsykin</surname><given-names>A.</given-names></name><name><surname>Solomon</surname><given-names>A.</given-names></name><name><surname>Smith</surname><given-names>K.</given-names></name><name><surname>Ludford-Menting</surname><given-names>M.</given-names></name><name><surname>Hooker</surname><given-names>D.J.</given-names></name></person-group><article-title>Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients</article-title><source>Science</source><volume>270</volume><year>1995</year><fpage>988</fpage><lpage>991</lpage><pub-id pub-id-type="pmid">7481804</pub-id></element-citation></ref><ref id="bib40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baba</surname><given-names>T.W.</given-names></name><name><surname>Liska</surname><given-names>V.</given-names></name><name><surname>Khimani</surname><given-names>A.H.</given-names></name></person-group><article-title>Live-attenuated, multiply deleted SIV causes AIDS in infants and adult macaques</article-title><source>Nat Med</source><volume>5</volume><year>1995</year><fpage>194</fpage><lpage>203</lpage></element-citation></ref><ref id="bib41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenough</surname><given-names>T.C.</given-names></name><name><surname>Sullivan</surname><given-names>L.</given-names></name><name><surname>Desrosiers</surname><given-names>R.C.</given-names></name></person-group><article-title>Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1</article-title><source>N Engl J Med</source><volume>340</volume><year>1999</year><fpage>236</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">9917232</pub-id></element-citation></ref><ref id="bib42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawai</surname><given-names>E.T.</given-names></name><name><surname>Hamza</surname><given-names>M.S.</given-names></name><name><surname>Ye</surname><given-names>M.</given-names></name><name><surname>Shaw</surname><given-names>K.E.</given-names></name><name><surname>Luciw</surname><given-names>P.A.</given-names></name></person-group><article-title>Pathogenic conversion of live attenuated SIV vaccine is associated with expression of truncated</article-title><source>Nef J Virol</source><volume>74</volume><year>2000</year><fpage>2038</fpage><lpage>2045</lpage><pub-id pub-id-type="pmid">10644378</pub-id></element-citation></ref><ref id="bib43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahn</surname><given-names>J.O.</given-names></name><name><surname>Cherng</surname><given-names>D.W.</given-names></name><name><surname>Mayer</surname><given-names>K.</given-names></name><name><surname>Murray</surname><given-names>H.</given-names></name><name><surname>Lagakos</surname><given-names>S.</given-names></name></person-group><article-title>Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected whith HIV having 300 to 549 &#x000d7; 10<sup>6</sup>/L CD4 cell counts: A randomized controlled trial</article-title><source>JAMA</source><volume>284</volume><year>2000</year><fpage>2193</fpage><lpage>2202</lpage><pub-id pub-id-type="pmid">11056590</pub-id></element-citation></ref><ref id="bib44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Francis</surname><given-names>D.P.</given-names></name><name><surname>Gregory</surname><given-names>T.</given-names></name><name><surname>McElrath</surname><given-names>M.J.</given-names></name></person-group><article-title>Advancing AIDSVAX to phase 3. Safety, immunogencity, and plans for phase 3</article-title><source>AIDS Res Hum Retroviruses</source><volume>14</volume><year>1998</year><fpage>25</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">9453248</pub-id></element-citation></ref><ref id="bib45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mascola</surname><given-names>J.R.</given-names></name><name><surname>Snyder</surname><given-names>S.W.</given-names></name><name><surname>Weislow</surname><given-names>O.Sl.</given-names></name></person-group><article-title>Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1</article-title><source>J Infect Dis</source><volume>173</volume><year>1996</year><fpage>34</fpage><lpage>48</lpage></element-citation></ref><ref id="bib46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallo</surname><given-names>R.C.</given-names></name></person-group><article-title>Tat as one key to HIV-induced immune pathogenesis and Tat toxoid as an important component of a vaccine</article-title><source>Proc Natl Acad Sci U S A</source><volume>96</volume><year>1999</year><fpage>8324</fpage><lpage>8326</lpage><pub-id pub-id-type="pmid">10411869</pub-id></element-citation></ref><ref id="bib47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bukawa</surname><given-names>H.</given-names></name><name><surname>Sekigawa</surname><given-names>K.</given-names></name><name><surname>Hamajima</surname><given-names>K.</given-names></name><name><surname>Fujushima</surname><given-names>J.</given-names></name><name><surname>Yamada</surname><given-names>Y.</given-names></name><name><surname>Kiyono</surname><given-names>H.</given-names></name></person-group><article-title>Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate</article-title><source>Nature Med</source><volume>1</volume><year>1995</year><fpage>681</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">7585151</pub-id></element-citation></ref><ref id="bib48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seth</surname><given-names>A.</given-names></name><name><surname>Ourmanov</surname><given-names>I.</given-names></name><name><surname>Schmith</surname><given-names>J.E.</given-names></name><name><surname>Kuroda</surname><given-names>M.J.</given-names></name><name><surname>Lifton</surname><given-names>M.A.</given-names></name><name><surname>Mickerson</surname><given-names>C.E.</given-names></name></person-group><article-title>Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge</article-title><source>J Virol</source><volume>74</volume><year>2000</year><fpage>2502</fpage><lpage>2509</lpage><pub-id pub-id-type="pmid">10684264</pub-id></element-citation></ref><ref id="bib49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiver</surname><given-names>J.W.</given-names></name><name><surname>Fu</surname><given-names>T.M.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Casimiro</surname><given-names>D.R.</given-names></name><name><surname>Davis</surname><given-names>M.E.</given-names></name><name><surname>Evans</surname><given-names>R.K.</given-names></name></person-group><article-title>Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity</article-title><source>Nature</source><volume>415</volume><year>2002</year><fpage>331</fpage><lpage>335</lpage><pub-id pub-id-type="pmid">11797011</pub-id></element-citation></ref><ref id="bib50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honda</surname><given-names>M.</given-names></name><name><surname>Matsuo</surname><given-names>K.</given-names></name><name><surname>Nakasone</surname><given-names>T.</given-names></name><name><surname>Okamoto</surname><given-names>Y.</given-names></name><name><surname>Yoshikazi</surname><given-names>H.</given-names></name><name><surname>Kitamura</surname><given-names>K.</given-names></name></person-group><article-title>Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant <italic>Mycobacterium bovis</italic> bacillus Calmette-Gu&#x000e9;rin vector candidate vaccine for human immunodeficiency virus type 1 in small animals</article-title><source>Proc Natl Acad Sci U S A</source><volume>92</volume><year>1995</year><fpage>10693</fpage><lpage>10697</lpage><pub-id pub-id-type="pmid">7479867</pub-id></element-citation></ref><ref id="bib51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trono</surname><given-names>D.</given-names></name></person-group><article-title>Lentiviral vectors: turning a deadly foe into a therapeutic agent</article-title><source>Gene Ther</source><volume>7</volume><year>2000</year><fpage>20</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">10680011</pub-id></element-citation></ref><ref id="bib52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyer</surname><given-names>J.D.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Ugen</surname><given-names>K.</given-names></name><name><surname>Cohen</surname><given-names>A.D.</given-names></name><name><surname>Ahn</surname><given-names>L.</given-names></name><name><surname>Schuman</surname><given-names>K.</given-names></name></person-group><article-title>HIV-1 DNA vaccines and chemokines</article-title><source>Vaccine</source><volume>17</volume><issue>Suppl 2</issue><year>1999</year><fpage>S53</fpage><lpage>S64</lpage></element-citation></ref><ref id="bib53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barouch</surname><given-names>D.H.</given-names></name><name><surname>Craiu</surname><given-names>A.</given-names></name><name><surname>Kuroda</surname><given-names>M.J.</given-names></name><name><surname>Schmitz</surname><given-names>J.E.</given-names></name><name><surname>Zheng</surname><given-names>X.X.</given-names></name><name><surname>Santra</surname><given-names>S.</given-names></name></person-group><article-title>Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys</article-title><source>Proc Natl Acad Sci U S A</source><volume>97</volume><year>2000</year><fpage>4192</fpage><lpage>4197</lpage><pub-id pub-id-type="pmid">10759543</pub-id></element-citation></ref><ref id="bib54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gherardi</surname><given-names>M.M.</given-names></name><name><surname>Ram&#x000ed;rez</surname><given-names>J.C.</given-names></name><name><surname>Esteban</surname><given-names>M.</given-names></name></person-group><article-title>IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system</article-title><source>J Gen Virol</source><volume>84</volume><year>2003</year><fpage>1961</fpage><lpage>1972</lpage><pub-id pub-id-type="pmid">12867626</pub-id></element-citation></ref><ref id="bib55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Rodrigues</surname><given-names>M.</given-names></name><name><surname>Rodr&#x000ed;guez</surname><given-names>D.</given-names></name><name><surname>Rodr&#x000ed;guez</surname><given-names>J.R.</given-names></name><name><surname>Esteban</surname><given-names>M.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name></person-group><article-title>Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+T-cell-mediated protective immunity against malaria</article-title><source>Proc Natl Acad Sci U S A</source><volume>90</volume><year>1993</year><fpage>5214</fpage><lpage>5218</lpage><pub-id pub-id-type="pmid">7685119</pub-id></element-citation></ref><ref id="bib56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nitayaphan</surname><given-names>S.</given-names></name><name><surname>Brown</surname><given-names>A.E.</given-names></name></person-group><article-title>Preventive HIV vaccine development in Thailand</article-title><source>AIDS</source><volume>S1</volume><year>1998</year><fpage>55</fpage><lpage>61</lpage></element-citation></ref><ref id="bib57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ready</surname><given-names>T.</given-names></name></person-group><article-title>AIDSVAX flop leaves vaccine field unscathed</article-title><source>Nat Med</source><volume>9</volume><year>2003</year><fpage>376</fpage></element-citation></ref><ref id="bib58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burton</surname><given-names>D.R.</given-names></name><name><surname>Desrosiers</surname><given-names>R.C.</given-names></name><name><surname>Doms</surname><given-names>R.W.</given-names></name><name><surname>Feinberg</surname><given-names>M.B.</given-names></name><name><surname>Gallo</surname><given-names>R.C.</given-names></name><name><surname>Hahn</surname><given-names>B.</given-names></name></person-group><article-title>Public health. A sound rationale needed for phase III HIV-1 vaccine trials</article-title><source>Science</source><volume>303</volume><year>2004</year><fpage>16</fpage></element-citation></ref><ref id="bib59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNeil</surname><given-names>J.G.</given-names></name><name><surname>Johnston</surname><given-names>M.I.</given-names></name><name><surname>Birx</surname><given-names>D.L.</given-names></name><name><surname>Tramont</surname><given-names>E.C.</given-names></name></person-group><article-title>Policy rebuttal. HIV vaccine trial justified</article-title><source>Science</source><volume>303</volume><year>2004</year><fpage>961</fpage><pub-id pub-id-type="pmid">14963313</pub-id></element-citation></ref><ref id="bib60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>T.G.</given-names></name><name><surname>Keefer</surname><given-names>M.C.</given-names></name><name><surname>Weinhold</surname><given-names>K.J.</given-names></name><name><surname>Wolff</surname><given-names>M.</given-names></name><name><surname>Montefiori</surname><given-names>D.</given-names></name><name><surname>Gorse</surname><given-names>G.J.</given-names></name></person-group><article-title>A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers</article-title><source>J Infect Dis</source><volume>180</volume><year>1999</year><fpage>290</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">10395842</pub-id></element-citation></ref><ref id="bib61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanke</surname><given-names>T.</given-names></name><name><surname>Samuel</surname><given-names>R.V.</given-names></name><name><surname>Blanchard</surname><given-names>T.J.</given-names></name><name><surname>Neumank</surname><given-names>V.C.</given-names></name><name><surname>Allen</surname><given-names>T.M.</given-names></name><name><surname>Boyson</surname><given-names>J.E.</given-names></name></person-group><article-title>Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA primemodified vaccinia virus ankara boost vaccination regimen</article-title><source>J Virol</source><volume>73</volume><year>1999</year><fpage>7524</fpage><lpage>7532</lpage><pub-id pub-id-type="pmid">10438842</pub-id></element-citation></ref><ref id="bib62"><label>62.</label><mixed-citation publication-type="other">Desrosiers R. Why an HIV vaccine is not currently within our grasp. XI CROI, San Francisco 2004 [abstract 109].</mixed-citation></ref><ref id="bib63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>G.</given-names></name><name><surname>Humphrey</surname><given-names>W.</given-names></name><name><surname>McElrath</surname><given-names>M.J.</given-names></name></person-group><article-title>Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers</article-title><source>Proc Natl Acad Sci U S A</source><volume>94</volume><year>1997</year><fpage>396</fpage><lpage>401</lpage></element-citation></ref><ref id="bib64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verrier</surname><given-names>F.</given-names></name><name><surname>Burda</surname><given-names>S.</given-names></name><name><surname>Belshe</surname><given-names>R.</given-names></name><name><surname>Duliege</surname><given-names>A.M.</given-names></name><name><surname>Excler</surname><given-names>J.L.</given-names></name><name><surname>Klein</surname><given-names>M.</given-names></name></person-group><article-title>A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates</article-title><source>J Virol</source><volume>74</volume><year>2000</year><fpage>10025</fpage><lpage>10033</lpage><pub-id pub-id-type="pmid">11024131</pub-id></element-citation></ref><ref id="bib65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloom</surname><given-names>B.R.</given-names></name></person-group><article-title>The highest attainable standard: ethical issues in AIDS vaccines</article-title><source>Science</source><volume>279</volume><year>1998</year><fpage>186</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">9446225</pub-id></element-citation></ref><ref id="bib66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boily</surname><given-names>M.C.</given-names></name><name><surname>Masse</surname><given-names>B.R.</given-names></name><name><surname>Desai</surname><given-names>K.</given-names></name><name><surname>Alary</surname><given-names>M.</given-names></name><name><surname>Anderson</surname><given-names>R.M.</given-names></name></person-group><article-title>Some important issues in the planning of phase III HIV vaccine efficacy trials</article-title><source>Vaccine</source><volume>17</volume><year>1999</year><fpage>989</fpage><lpage>1004</lpage><pub-id pub-id-type="pmid">10067708</pub-id></element-citation></ref><ref id="bib67"><label>67.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>UNAIDS</collab></person-group><chapter-title>Ethical considerations in HIV preventive vaccine research (document UNAIDS/00.07E</chapter-title><year>2000</year><publisher-name>WHO</publisher-name><publisher-loc>Gen&#x000e8;ve</publisher-loc></element-citation></ref><ref id="bib68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klausner</surname><given-names>R.D.</given-names></name><name><surname>Fauci</surname><given-names>A.S.</given-names></name><name><surname>Corey</surname><given-names>L.</given-names></name><name><surname>Nabel</surname><given-names>G.J.</given-names></name><name><surname>Gayle</surname><given-names>H.</given-names></name><name><surname>Berkley</surname><given-names>S.</given-names></name></person-group><article-title>The needfor a global HIV vaccine enterprise</article-title><source>Science</source><volume>300</volume><year>2003</year><fpage>2036</fpage><lpage>2038</lpage><pub-id pub-id-type="pmid">12829768</pub-id></element-citation></ref></ref-list></back></article>